RELATIONSHIP BETWEEN BACILLE CALMETTE-GUERIN (BCG) STRAINS AND THE EFFICACY OF BCG VACCINE IN THE PREVENTION OF TUBERCULOSIS
RELATIONSHIP BETWEEN BACILLE CALMETTE-GUERIN (BCG) STRAINS AND THE EFFICACY OF BCG VACCINE IN THE PREVENTION OF TUBERCULOSIS
复制标题
DOI：
10.1093/clinids/20.1.126
复制
发表时间：
1995-01-01
影响因子：
11.8
通讯作者：
COLDITZ, GA
中科院分区：
文献类型：
--
作者：
BREWER, TF;COLDITZ, GA
自1921年以来，用于预防结核病的卡介苗（BCG）疫苗接种已经用于人类。此外，在>60年的时间里，已经可以基于体外和体内测试来分离BCG菌株（在此定义为在特定实验室中保存并在特定试验或一组试验中使用的BCG疫苗）。研究人员得出结论，在人类疗效试验中使用的BCG菌株的差异可能是这些试验中报告的结核病保护水平范围广泛的原因，我们回顾了最近荟萃分析中所包括的试验中使用的单独菌株的发展，并检查了不同BCG菌株的保护功效的数据，讨论了将体外和体内试验结果与人体保护效力相关联的困难。从人体研究中获得的有限数据表明，用于接种疫苗的BCG菌株不是预防结核病总体效力的重要决定因素。
Bacille Calmette-Guerin (BCG) vaccination for the prevention of tuberculosis has been used in humans since 1921, Furthermore, for >60 years it has been possible to separate BCG strains (defined here as a BCG vaccine maintained in a particular laboratory and used in a particular trial or set of trials) on the basis of in vitro and in vivo tests. Investigators have concluded that differences in the BCG strains used in efficacy trials on humans may be responsible for the wide range in levels of protection from tuberculosis reported in those trials, We review the development of the separate strains used in the trials included in a recent meta-analysis and examine data for and against the protective efficacy of different BCG strains, The difficulties in correlating results of in vitro and in vivo tests with protective efficacy in humans are discussed, The limited data available from human studies suggest that the BCG strain used for vaccination is not a significant determinant of the overall efficacy in the prevention of tuberculosis.